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Abstract
Background: Cutaneous leishmaniasis is a vector-borne disease that is in Ethiopia mainly caused by the parasite Leishmania
aethiopica. This neglected tropical disease is common in rural areas and causes serious morbidity. Persistent nonhealing
cutaneous leishmaniasis has been associated with poor T cell mediated responses; however, the underlying mechanisms are
not well understood.
Methodology/Principal Findings: We have recently shown in an experimental model of cutaneous leishmaniasis that
arginase-induced L-arginine metabolism suppresses antigen-specific T cell responses at the site of pathology, but not in the
periphery. To test whether these results translate to human disease, we recruited patients presenting with localized lesions
of cutaneous leishmaniasis and assessed the levels of arginase activity in cells isolated from peripheral blood and from skin
biopsies. Arginase activity was similar in peripheral blood mononuclear cells (PBMCs) from patients and healthy controls. In
sharp contrast, arginase activity was significantly increased in lesion biopsies of patients with localized cutaneous
leishmaniasis as compared with controls. Furthermore, we found that the expression levels of CD3f, CD4 and CD8 molecules
were considerably lower at the site of pathology as compared to those observed in paired PBMCs.
Conclusion: Our results suggest that increased arginase in lesions of patients with cutaneous leishmaniasis might play a role
in the pathogenesis of the disease by impairing T cell effector functions.
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Introduction
The leishmaniases are a complex of vector-borne diseases caused
by the parasite Leishmania. They are neglected tropical diseases, that
affect the poorest population and cause major morbidity and
mortality, estimated to 2.4 million disability-adjusted life-years [1].
Currently, these diseases affect an estimated 12 million people in 88
countries, and approximately 350 million people are at risk [2].
Leishmaniases can present with a wide range of clinical syndromes
that may be cutaneous or visceral: cutaneous leishmaniasis (CL) is
manifested as localized (LCL), mucocutaneous (MCL) or mucosal
(ML) and diffuse (DCL) disease [3]. Visceral leishmaniasis (VL), the
most severe form of leishmaniasis, is a systemic disease, in which the
mortality rate can be as high as 100% if left untreated. Adequate
treatment results in an overall cure rate of .90% [3].
Leishmaniasis is one of the most important vector-borne
diseases in Ethiopia, where it is mainly prevalent in the highlands.
However, there is still only very limited information from
epidemiological studies about the number of VL and CL cases.
According to the Ethiopian National Guidelines for the Diagnosis
and Treatment of Leishmaniasis, Ethiopia has the second largest
number of VL cases in sub-Saharan Africa with an estimated 4500
to 5000 new cases every year. VL is associated with high mortality
and morbidity, and is worsened by poor nutrition, isolated location
of VL endemic areas and co-infections with HIV [4]. Similarly,
there is limited data about the frequency and distribution of CL in
Ethiopia [5,6,7,8,9,10,11]. CL in Ethiopia is mainly caused by
Leishmania (L.) aethiopica, and rarely by L. tropica or L. major [12] and
can manifest as LCL, with localized cutaneous nodular lesions,
that can ulcerate and heal, leaving depressive scars (LCL); DCL,
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which is characterized by disseminated nodular lesions; and MCL,
with lesions spreading into the nasal and/or oral mucosa [13].
LCL usually heals spontaneously within 1 year [7], however,
persistent LCL as well as MCL and DCL require treatment;
relapses are frequent after treatment in DCL and MCL [3,12].
One experimental model of cutaneous leishmaniasis caused by L.
major has been extensively studied: in this model, infection of BALB/
c mice induces progressive nonhealing lesions; this inability to
control infection has been associated with a polarized T helper (Th)
2 response. In contrast, C57BL/6 or CBA mice can efficiently
control parasite replication and become immune to secondary
challenge, this has been ascribed to a Th1 response [14,15,16]. In
sharp contrast, infections of different strains of mice and other
rodents with L. aethiopica does not lead to obvious clinical symptoms,
even though parasites can be isolated from L. aethiopica infected
BALB/c mice [17,18,19]. The exceptions are the Syrian and the
CBC hamsters, which can be successfully infected into the nose, and
produce lesions similar to those observed in DCL patients [19].
There is also very limited information on the immune response in L.
aethiopica infected patients. It has been shown that LCL, but not
DCL patients will respond to leishmanin skin test [20]. Further-
more, whereas mononuclear cells from LCL patients can proliferate
and express cytokines in vitro in response to antigenic restimulation,
those from DCL patients have an impaired capacity to become
activated [20,21,22]. While the mechanisms responsible for this
hyporesponsiveness are not yet clarified, it has been suggested that
lower levels of IFN-c and increased expression of IL-10 might
contribute to immunosuppression in DCL patients [21]. CD8+ T
cells and NK cells may also play a protective role [23].
The catabolism of L-arginine by arginase is emerging as a critical
mechanism of immune regulation [24,25,26]. Arginase, which is
typically considered to be an enzyme of the urea cycle in the liver,
hydrolyzes L-arginine to urea and ornithine, which is further
metabolized into polyamines. Arginase can be upregulated by
cytokines such as IL-4 and IL-13, which can synergize with IL-10
and IL-21, as well as by inflammatory stimuli (summarized in [26]).
Upregulation of arginase in myeloid cells results in increased
uptake of extracellular L-arginine, thus reducing L-arginine levels
in the microenvironment. Since T cells unconditionally require L-
arginine for efficient activation, decrease in L-arginine results in
impaired T cell responses [24,25,26]. The downregulation of T
cell responses by arginase-induced L-arginine depletion has been
studied in several cancer models [25], in corneal transplantation
[27] and pregnancy [28] and increased arginase activities have
been associated with a variety of infectious diseases such as
schistosomiasis [29], trypanosomiasis [30], tuberculosis [31],
leishmaniasis [32,33], hepatitis B [34] and HIV [35].
We have recently shown in an experimental model of cutaneous
leishmaniasis that high arginase activity is a hallmark of
nonhealing disease [32] and that this increased arginase contrib-
utes to persistent nonhealing leishmaniasis by causing local
suppression of T cell responses [33].
To determine whether our experimental data translate to
human disease, we tested whether enhanced arginase activity is
present in biopsies of LCL patients and whether this coincides with
T cell suppression.
Methods
Subjects and sample collection
The study was approved by the Ethiopian National Research
Ethics Review Committee (NRERC, reference 310/18/03), by
Addis Ababa University Medical Faculty Institutional Review
Board (IRB, reference 023/2009) and by the Joint UCL/UCLH
Committees on the Ethics of Human Research (Committee Alpha,
reference 09/H0715/93). For this study, a cohort of 15 patients
with localized cutaneous leishmaniasis was recruited from the
Leishmaniasis Research and Diagnostic Laboratory, Addis Ababa
University, Ethiopia. Ten healthy controls were recruited among
the staff of the hospital; they had careful physical examinations
and showed no cutaneous lesions and had no prior history of
cutaneous leishmaniasis. Informed written consent was obtained
from each patient and control and all data analyzed were
anonymized. 8–20 ml of blood in EDTA tubes and 1 or 2
biopsies (3 or 4 mm) were collected from each patient from the
edge of the active lesion before the treatment started; or from
intact skin on one forearm from the healthy controls. Patients
positive for HIV were excluded from the study. Both the biopsies
and blood were processed immediately after harvesting. Peripheral
blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation on HistopaqueH-1077 (Sigma). Cells were
washed in phosphate buffered saline (PBS) and were immediately
used for flow cytometry; PBMCs used for arginase and protein
determination were immediately resuspended in lysis buffer (0.1%
Triton X-100, 25 mM Tris-HCl and 10 mM MnCl2, Sigma) and
then frozen at 220uC until further use. Biopsies were collected in
PBS and homogenized in PBS for flow cytometry or in lysis buffer
and frozen until arginase and protein assays were performed.
Determination of arginase activity
The enzymatic activity of arginase was measured as previously
described [35]. Briefly, cell lysates were activated by heating for
10 min at 56uC. L-arginine hydrolysis was conducted by
incubating the activated lysates with 50 mL 0.5 M L-arginine
(pH 9.7) at 37uC for 60 min. The reaction was stopped with
400 mL H2SO4 (96%)/H3PO4(85%)/H2O (1:3:7, v/v/v). Twenty
mL a-isonitrosopropiophenone (ISPF, dissolved in 100% ethanol,
Sigma) was added and incubated for 45 min at 100uC, followed by
30 min at 4uC. The optical density (OD) was measured at 550 nm.
Author Summary
The leishmaniases are a complex of diseases caused by
Leishmania parasites. Currently, the diseases affect an
estimated 12 million people in 88 countries, and approx-
imately 350 million more people are at risk. The leishman-
iases belong to the most neglected tropical diseases,
affecting the poorest populations, for whom access to
diagnosis and effective treatment are often not available.
Leishmania parasites infect cells of the immune system
called macrophages, which have the capacity to eliminate
the intracellular parasites when they receive the appropri-
ate signals from other cells of the immune system. In
nonhealing persistent leishmaniasis, lymphocytes are
unable to transmit the signals to macrophages required
to kill the intracellular parasites. The local upregulation of
the enzyme arginase has been shown to impair lympho-
cyte effector functions at the site of pathology. In this
study, we tested the activity of this enzyme in skin lesions
of patients presenting with localized cutaneous leishman-
iasis. Our results show that arginase is highly upregulated
in these lesions. This increase in arginase activity coincides
with lower expression of a signalling molecule in lympho-
cytes, which is essential for efficient activation of these
cells. These results suggest that increased arginase
expression in the localized cutaneous lesions might
contribute to persistent disease in patients presenting
with cutaneous leishmaniasis.
Arginase in Cutaneous Leishmaniasis Patients
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One unit of enzyme activity is defined as the amount of enzyme
that catalyzes the formation of 1 mmol of urea per min.
Protein determination
To determine the protein concentration of each PBMC sample,
serial dilutions of each PBMC sample were made in PBS (Sigma).
BCA Protein Assay Reagent (Pierce) was added to each PBMC
dilution following supplier’s recommendations. A bovine serum
albumin (BSA) standard (Pierce) was serially diluted using PBS.
Following 30 min incubation at 37uC, the optical density (OD)
was measured at 570 nm.
Flow cytometry
Antibodies used were as follows: anti-CD4 (clone 13B8.2,
Beckman Coulter), anti-CD8 (clone RPA-T8, BD Biosciences),
anti-CD3f (Santa Cruz: clone 6B10.2), anti-CD14 (BD Pharmin-
gen: cloneM5E2), anti-CD15 (Clone H198, BD Pharmingen);
anti-arginase I (HyCult Biotechnology: clone 6G3) and the isotype
control (BD Pharmingen: clone MOPC21) were coupled with
Alexa FluorR 488 (Molecular Probes). Cells were washed with
PBS, the fixation step was performed with 2% formaldehyde in
PBS and the permeabilisation step with 0.5% saponin in PBS.
The determination of intracellular arginase was performed as
described in [35]. The percentages for the isotype controls were
,1.5%. Acquisition was performed using a FACSCalibur (BD
Biosciences) and data were analyzed using Summit v4.3 software.
Statistical analyzes
Data were evaluated for statistical differences using a two-tailed
Mann-Whitney test, Wilcoxon pair test or Spearman’s rank test
when appropriate (GraphPad Prism 5) and differences were
considered statistically significant at p,0.05.
Results
Clinical data
Fifteen patients with lesions of LCL that were typical in their
history and appearance were recruited for this study. All patients
lived or had travelled in regions of Ethiopia endemic for CL
caused by L. aethiopica; however, the infecting parasites were not
typed. The diagnosis was confirmed by demonstration of
amastigotes in skin scraping and growth of promastigotes in
NNN medium. Out of the 15 patients recruited in this study, 7
were female and 8 were male, with a median age of 1962.4
(Table 1). The large majority of the patients presented with
nodular lesions (13 patients), 1 patient with an ulcerated lesion and
1 patient with ulcerated and nodular mixed lesions. Ten patients
had 1 lesion and 5 patients had 2 lesions. The majority of the
lesions (12) were found on the face (forehead, ear, cheek, lip, nose),
3 on the forearm, 1 on the neck and 1 on a finger. The duration of
their illness ranged from 4 to 48 months (median 6 SEM: 12
months63.6): 7 patients had lesions for ,12 months and 8
patients had lesions for .12 months (Table 1).
Arginase activity and phenotype of arginase-expressing
cells in PBMCs
We first assessed the levels of arginase activity in PBMCs of
LCL patients and compared it with healthy controls. The arginase
activity was not statistically increased in the PBMCs of LCL
patients (54.5 vs 45.1 mU/mg protein, p=0.2751, Figure 1). We
then determined the phenotype of arginase expressing cells in the
PBMCs of LCL patients and controls and the results showed that
the cells expressing arginase are low-density granulocytes
(LDGs=CD15+ CD14low, Figure 2A). In all 15 patients tested,
.93% of CD15+ cells expressed arginase. Similarly, the large
majority of arginase-expressing cells in the PBMCs obtained from
the controls were CD15+ (data not illustrated). In contrast, the
frequency of arginase-expressing monocytes (CD14+ CD152
arginase+) was below 1% (Figure 2B), except for 2 patients
(1.1% and 1.2%, data not illustrated). Both cells types - LDGs and
monocytes - were present in distinct regions of the forward and
side scatter (FSC/SSC) dotplot: LDGs were found in region R2
(Figure 2C) and monocytes in region R3 (Figure 2C). The
frequencies of LDGs (Figure 3A), monocytes (Figure 3B) and the
ratio of LDGs/monocytes (Figure 3C) in PBMCs were similar
between controls and LCL patients (median6sem: %CD15+:
Table 1. Clinical data.
Patient Sex Age Lesion type Lesion size (mm) # lesions Lesion site Duration of illness (months)
1 F 17 ulcerated nd 1 Forearm 12
2 M 17 nodular 24623 1 Nose 3
3 F 20 nodular 35620/22622 2 Nose/forearm 36
4 F 13 nodular 40650/10610 2 Forearm 14
5 M 19 nodular nd 1 Ear 48
6 F 21 nodular 10610 1 Lower lip 6
7 M 23 nodular 10610 1 Nose 6
8 M 16 nodular 20623/1065 2 Forehead 4
9 M 11 nodular 47630 1 Forehead 12
10 M 21 mixed nd 2 Cheek/ear 14
11 F 11 nodular 10630 1 Cheek 12
12 M 19 nodular 10625 1 Nose 36
13 M 20 nodular 40680/nd 2 Neck 4
14 F 50 nodular 30640 1 Nose 4
15 F 12 nodular nd 1 finger 6
nd =not done.
doi:10.1371/journal.pntd.0001684.t001
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6.060.66 vs 5.761.16; %CD14+ cells: 10.061.48 vs 10.261.21;
ratio CD15+/CD14+: 1.9060.43 vs 1.760.71, p.0.05).
The results presented in Figures 1, 2, and 3 show that the
arginase activity and frequency of arginase-expressing cells in
PBMCs of LCL patients are not significantly increased. These
results also establish that the arginase-expressing cells in the blood
of patients and controls are neutrophils.
Arginase activity in lesions of LCL patients
As shown in Figure 4, high levels of arginase activity were
measured in lesions of LCL patients; notably, they were
significantly higher than those measured in intact control skin
(279.2641.1 vs 18.866.3 mU/mg protein, p=0.0002). There was
no significant correlation between arginase activities and lesions
size or duration of lesions (p.0.05).
To identify the phenotype of arginase-expressing cells in the
lesions, we used the same combination of cell surface and
intracellular arginase labeling as for the PBMCs. We were able
Figure 1. Arginase activity in PBMCs from controls and LCL
patients. PBMCs from controls (n = 10) and LCL patients (n = 11) were
isolated by Ficoll gradient and the activity of arginase was measured by
enzymatic assay. Values represent median with interquartile range.
Statistical significance was determined by a two-tailed Mann-Whitney
test, ns = not significant.
doi:10.1371/journal.pntd.0001684.g001
Figure 2. Arginase-expressing cells in PBMCs are neutrophils. PBMCs were isolated by density gradient from the blood of LCL patients. The
phenotype of arginase-expressing cells was determined by flow cytometry. (A) Dot plot profile of CD15+ arginase+ cells; (B) dot plot profile of CD14+
arginase+ cells; (C) dot plot profile of forward (FSC) and side scatter (SSC). Data show the results of one representative experiment out of 15
independent experiments. Isotype control for arginase: 0.98%.
doi:10.1371/journal.pntd.0001684.g002
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to isolate enough cells (.1000 CD15+ cells) to be analyzed by flow
cytometry from homogenates of skin biopsy from 3 out of 10
patients, who had a 4 mm biopsy taken. A CD15+ population was
detected in patients’ biopsy (Figure 5), in a region that was similar
to that of LDGs detected in the PBMCs of the same patient (FSS/
SSC: LDGs=95/85, PBMCs= 101/82). In contrast, the frequen-
cy of CD14+ cells in the biopsies was very low (,250 events) and it
was therefore not possible to characterise these cells in detail.
These results show that arginase activity is considerably
increased in biopsied skin lesions of LCL in Ethiopia and suggest
that arginase-expressing CD15+ cells are also present in the lesions
of patients with cutaneous leishmaniasis in Ethiopia.
Figure 3. Frequency of neutrophils and monocytes in PBMCs. PBMCs were isolated by density gradient from the blood of controls (n = 10)
and LCL patients (n = 15) and the frequencies of CD15+ (A), CD14+ (B) cells and the ratio of CD15/CD14 (C) were determined by flow cytometry. Values
represent median with interquartile range. Statistical significance was determined by a two-tailed Mann-Whitney test, ns = not significant.
doi:10.1371/journal.pntd.0001684.g003
Figure 4. Arginase activity in skin lesions from controls and
LCL patients. Skin biopsies from controls (n = 6) and LCL patients
(n = 10) were homogenized and the activity of arginase was measured
by enzymatic assay. Values represent median with interquartile range.
Statistical significance was determined by a two-tailed Mann-Whitney
test.
doi:10.1371/journal.pntd.0001684.g004
Figure 5. Arginase-expressing cells in biopsy are neutrophils.
The phenotype of arginase-expressing cells in homogenates of skin
biopsies was determined by flow cytometry by using a combination of
antibodies against CD14, CD15 and arginase. Data show the results of
one representative experiment out of three independent experiments.
doi:10.1371/journal.pntd.0001684.g005
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Comparison of expression levels of CD3f, CD4 and CD8
in biopsies and PBMCs
Our results depicted in Figures 1 and 4 and summarized in
Figure 6 show that cells isolated from cutaneous lesions express
significantly higher levels of arginase activity per mg of protein as
compared to cells isolated from peripheral blood of the same LCL
patients (n = 10, 279.2641.1 vs 53.466.4, p=0.0020). We have
previously shown that in a mouse model of CL, high arginase
activity causes depletion of L-arginine, which impairs antigen-
specific T cell responses [33]. Decreased expression of CD3f in T
cells has been extensively used as marker of arginase-induced T
cell suppression [24,25]. Therefore, here we determined whether
high arginase activity observed in the cutaneous lesions of patients
coincides with lower expression levels of CD3f in CD4+ and CD8+
T cells as compared to those in the peripheral blood. First we
compared the frequency and ratio of CD4+ and CD8+ T cells in the
blood and the biopsies and show that the percentage of CD4+T cells
is similar in both compartments (Figure 7A). Interestingly, there was
a higher frequency of CD8+ T cells in biopsies (p=0.0071,
Figure 7B). The ratio of CD4/CD8+ T cells was higher in the
PBMCs, but it was not statistically significant (p=0.075, Figure 7C).
Of note, these frequencies and ratios were also comparable between
PBMCs isolated from the blood from controls and patients (Table 2).
Next, we measured the mean fluorescence intensity (MFI) of CD3f
in T cells from homogenates of skin biopsy and compared it to those
in cells isolated from the blood of the same patient. Results in
Figures 8A–C show that the CD3f MFI in CD4+ T cells was lower
in the biopsies of 10 out of 12 patients (p=0.0024). Interestingly, the
MFI of the CD4 molecule on T cells (CD4 MFI) was also lower in
the biopsies as compared to the blood in 10 out of 12 patients
(p=0.0024, Figures 8D–F). Similar results were obtained with the
expression levels of CD3f and CD8 molecules: it was decreased in
Figure 6. Arginase activity in cells isolated from peripheral
blood and skin biopsies from LCL patients. Arginase activity was
measured by enzymatic assay in skin homogenates and PBMCs from
LCL patients (n = 10). Statistical significance was determined by a
Wilcoxon paired test.
doi:10.1371/journal.pntd.0001684.g006
Figure 7. Frequency of CD4+ and CD8+ T cells in PBMCs and biopsies of LCL patients. The frequencies of CD4+ and CD8+ T cells was
determined in cells isolated from the blood and from the biopsies of LCL patients (n = 15) by flow cytometry. (A) % of CD4+ T cells; (B) % of CD8+ T
cells; (C) ratio of CD4/CD8. Values represent median with interquartile range. Statistical significance was determined by a two-tailed Mann-Whitney
test, ns = not significant.
doi:10.1371/journal.pntd.0001684.g007
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11 out of 12 patients tested (p=0.0010, Figures 9A–C); moreover,
CD8 MFI were lower in the biopsies of all patients tested
(p=0.0005, Figures 9D–F).
These results show that the expression levels of CD3f, as well as
CD4 and CD8 molecules are reduced in the skin biopsies as
compared to those present in the blood of the same patient.
Discussion
Here we showed that our results obtained in a mouse model
translate to human disease: the levels of arginase activity were
similar in the cells isolated from peripheral blood of LCL patients
and controls, showing that arginase is not increased in the
periphery following infection with Leishmania parasites. In sharp
contrast, arginase was clearly increased in skin lesions of LCL
patients as compared to intact skin. Moreover, arginase activity
was considerably higher in the cells isolated from the skin biopsies
as compared to the PBMCs. These results are in agreement with
those obtained in the mouse model, where we showed that
arginase is upregulated at the site of pathology, but not in the
periphery [33].
The cells expressing arginase were identified as neutrophils both
in the blood and in the lesions. In the blood, these cells co-purify
with PBMCs and have therefore been named low-density
granulocytes (LDGs). We and others have already described these
cells [36] [28,35,37] and have shown that they were likely to be
activated granulocytes [38]. Whereas we have previously shown
that bone marrow derived macrophages activated with IL-4 or IL-
4 and IL-10 upregulate arginase [32,39,40], we have not yet
identified the phenotype of arginase-expressing cells in lesions of
BALB/c mice infected with L. major. We have previously shown
that both macrophages and neutrophils are recruited into lesions
of L. major infected mice [41,42], therefore we cannot exclude that
Table 2. Ratio of CD4/CD8+ T cells in PBMCs isolated from
controls (n = 10) and LCL patients (n = 12).
% CD4 % CD8 CD4/CD8
Controls 39.6+/22.2 26.2+/22.6 1.4+/20.1
Patients 40.2+/22.0 25.6+/22.0 1.4+/20.2
Values represent median 6 sem.
doi:10.1371/journal.pntd.0001684.t002
Figure 8. CD3f and CD4 MFI in PBMCs and biopsies of LCL patients. The MFI of CD3f in CD4+ T cells (A) and MFI of CD4 molecule (D) were
compared between cells isolated from the blood and from the biopsies of LCL patients (n = 12) by flow cytometry; (B) representative histogram of MFI
of CD3f in CD4+ T cells (open histogram = biopsies, closed histogram=PBMCs); (E) representative histogram of MFI of CD4 (open
histogram=biopsies, closed histogram=PBMCs); (C) % decrease in CD3f MFI in CD4 (black bar =median); (F) % decrease in CD4. Statistical
significance was determined by a Wilcoxon paired test.
doi:10.1371/journal.pntd.0001684.g008
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in these lesions, macrophage and/or neutrophils express arginase.
We could identify only low numbers of macrophages in the lesions
(,250 events), this was unexpected as Leishmania-infected macro-
phages can be identified in scrapings from cutaneous lesions and in
fixed biopsies [43,44]. It is possible that the technique used to
homogenize the lesions damages the macrophages and it is
therefore not possible to conclude from this study whether
macrophages also contribute to the overall arginase measured in
the lesions.
Increased arginase activity in macrophages has been shown to
favour parasite growth [32,45]. Leishmania parasites are taken up
by neutrophils (reviewed in [46,47] and it is possible that this gives
them a survival advantage. However, since they have not been
shown proliferate efficiently in neutrophils, here we favour the
hypothesis that neutrophil arginase affects both wound healing (1)
and T cell responses (2), two processes that are crucial in resolving
cutaneous lesions:
1. L-arginine is the substrate for both arginase and inducible
nitric oxide synthase (iNOS), which play an important role in
wound healing. Increased synthesis of nitric oxide (NO) by
NOS promotes processes such as angiogenesis, epithelialisation
and collagen synthesis, which are critical for tissue repair
[48,49,50]. On the other hand, arginase catabolises L-arginine
into ornithine, an essential precursor of polyamines and
proline, which are both required for wound healing. Therefore,
it is possible that arginase is increased in lesions of LCL patients
as part of the normal process of tissue repair. However,
arginase has also been shown to be overexpressed in
pathological wounds such as those found in psoriasis [51,52]
and diabetes [53]. Since NO production is reduced by arginase
via the depletion of L-arginine [54], it is possible that
upregulation of arginase might reduce the production of NO,
thereby not only compromising tissue repair, but also parasite
killing. Further, a study by Kavalukas et al. has recently shown
that arginase activity can delay wound healing [55], thus
arginase may have positive as well as detrimental roles
depending on the duration and the type of lesions.
2. Arginase-induced L-arginine catabolism is a well-established
mechanism of immune suppression [24,56] [26]. Depletion of
L-arginine has been shown in superficial wounds [50], in
psoriatic lesions [51] and lesion from L. major-infected mice
[33]. To assess whether high arginase expressed in the lesions
of LCL patients coincides with dysfunctional T cell responses
Figure 9. CD3f and CD8 MFI in PBMCs and biopsies of LCL patients. The MFI of CD3f in CD8+ T cells (A) and MFI of CD8 molecule (D) were
compared between cells isolated from the blood and from the biopsies of LCL patients (n = 12) by flow cytometry; (B) representative histogram of MFI
of CD3f in CD8+ T cells (open histogram=biopsies, closed histogram= PBMCs); (E) representative histogram of MFI of CD8 (open
histogram=biopsies, closed histogram=PBMCs); (C) % decrease in CD3f MFI in CD8 (black bar =median); (F) % decrease in CD8. Statistical
significance was determined by a Wilcoxon paired test.
doi:10.1371/journal.pntd.0001684.g009
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we measured the expression levels of CD3f in T cells. CD3f is
widely used as a marker of impaired T cell activation: its
downregulation coincides with impaired T cell functions such
as proliferation and cytokine production [57,58,59]. The
results presented here show that the MFI of CD3f is lower in
the CD4+ and CD8+ T cells isolated from the skin biopsies as
compared to those from the blood, suggesting that T cell
activation and function might be compromised in lesions from
LCL patients; this might contribute to their inability to mount
efficient immune responses to control parasite load and resolve
the lesions. Further, our results also show that the expression
levels of CD4 and CD8 molecules are lower on T cells isolated
from the biopsies as compared to those isolated from peripheral
blood. Antigenic modulation of the expression levels of these
molecules has already been shown [60,61]. Taken together, our
results suggest that upregulation of arginase in lesions of LCL
patients coincides with functional impairment of T cells.
Persistent leishmaniasis has been associated with immune
suppression [20,21,22]. The biopsies analyzed in the present
study were all collected from LCL patients. The observed natural
history of LCL is that ,70% heal within 12 months and 30%
within 24 months [7]. However, it is not possible to predict
whether a lesion will heal or become chronic and indeed, 8
patients had their lesions for 12 months or more. Therefore, we
propose that high arginase results in impaired T cell responses and
therefore contributes to the delay of healing that is characteristic in
LCL in Ethiopia. Of note, the majority of LCL lesions analysed
here were nodular and we cannot exclude that ulcerated lesions
might express different levels of arginase and/or CD3f. The
results of this study call for further work to analyse in detail
different types of LCL lesions.
Cutaneous leishmaniasis causes serious morbidity in Ethiopia.
The lesions, which are most commonly on the face, are chronic,
disfiguring and sometimes disabling, and cause significant social
stigma [62]. To date, the immunopathology of this disease has
been poorly understood. Here we show for the first time that
arginase is upregulated in lesions of patients with LCL and that
this coincides with reduced levels of CD3f expression in T cells.
Further study is needed to assess whether arginase-mediated L-
arginine metabolism is a key element in the outcome of human
leishmaniasis and this is currently ongoing in our laboratories.
Therapeutic interventions that can regulate arginase and L-
arginine metabolism might prove useful in the treatment of
cutaneous leishmaniasis, and possibly in visceral leishmaniasis.
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